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Abstract
Background: Low-level expression of O6 methylguanine-DNA-methyl transferase (MGMT) prolactinomas has been
noted previously in case reports, although what modulates MGMT expression remains unclear. This study therefore
aimed to delineate the factors regulating MGMT expression in prolactinomas.
Methods: We retrospectively reviewed 136 prolactinoma patients who were treated in our center between January
2000 and September 2013. Expression of MGMT, Ki-67, and p53 protein were examined by immunohistochemical
staining, and MGMT promoter methylation evaluated with methylation-specific PCR.
Results: MGMT immunopositivity was <25 % in 106/136 tumor specimens (77.94 %). MGMT immunoexpression was
positively correlated with age (r = 0.251, p = 0.003), but inversely correlated with p53 staining (r = −0.153, p = 0.021).
Moreover, reduced MGMT expression was more frequent in atypical prolactinomas (p = 0.044). Methylated MGMT
promoter was confirmed in 10/46 specimens (21.7 %), all of which had low level or absent MGMT staining. Both
p53 protein (r = −0.33, p = 0.025) and promoter methylation (r = −0.331, p = 0.025) were negatively associated with
MGMT expression. Multivariate logistic analysis indicated that age (odds ratio [OR] = 1.127. 95 % confidence interval
[CI] 1.027–1.236, p = 0.012) and p53 (OR = 0.116. 95 % CI 0.018–0.761, p = 0.025) staining were independent
determents of MGMT expression.
Conclusions: The majority of prolactinomas, especially atypical prolactinomas, showed low-level or no MGMT
immunoexpression, providing a rationale for the utility of temozolomide as an alternative to managing
prolactinomas. In summary, epigenetic and transcriptional regulation are involved in silencing MGMT expression.
Background
Prolactinomas are among the most prevalent secretory
pituitary adenomas and are usually controlled by dopa-
mine agonists, with or without adjuvant surgical and ra-
diation therapy [1]. However, there are limited treatment
options for patients who harbor drug-resistant prol-
actinomas, where surgical resection either failed or early
recurrence occurred after surgery or radiotherapy. Temo-
zolomide (TMZ) is an oral alkylating agent and has shown
promise against glioblastoma [2]. More recently, success-
ful use of TMZ in treating aggressive pituitary adenomas
and pituitary carcinomas has been widely reported [3].
However, the mechanism by which TMZ acts on pituitary
tumors remains unclear. Previous studies have docu-
mented that O6 methylguanine-DNA-methyl transferase
(MGMT) correlates with the response of glioblastomas to
TMZ [4, 5]. Similarly, low-level MGMT is also associated
with a better prognosis in TMZ-treated adenoma patients
[6]. Interestingly, prolactinomas are more sensitive to
TMZ, with 75 % of published cases showing a sustained
* Correspondence: zhuyongh@mail.sysu.edu.cn; wzwxr_1995@yahoo.com
†Equal contributors
2Key Laboratory of Pituitary Adenoma in Guangdong Province, Guangzhou
510080, China
1Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen
University, Haizhu, Yixian RdGuangdong, Guangzhou, China
Full list of author information is available at the end of the article
© 2015 Jiang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jiang et al. BMC Cancer  (2015) 15:644 
DOI 10.1186/s12885-015-1595-0
response [5]. However, accumulating evidence indicates
that low-level MGMT is more frequently observed in pro-
lactinomas [5, 7, 8], suggesting a potential association be-
tween responsiveness and reduced MGMT expression [5].
Despite the fact that MGMT expression might help pre-
dict prolactinoma response to TMZ, to our knowledge,
the expression profile of MGMT in prolactinomas has not
been systematically described.
The mechanisms underlying the genetic, epigenetic, and
transcriptional regulation of MGMT expression are not
fully understood [9–11]. Promoter methylation represents
one of the major factors silencing MGMT gene expression
and predicts a favorable outcome in patients with
glioblastomas exposed to TMZ [2]. However, systematic
studies have identified a role for MGMT promoter methy-
lation in silencing among pituitary adenomas [5, 6, 12].
Notably, recent data implies that promoter methylation is
not the leading mechanism contributing to low pituitary
adenoma MGMT expression [5, 7]. At the same time,
methylated MGMT promoters did not tend to correlate
with a response to TMZ exposure [5]. Moreover, although
the majority of sporadic pituitary adenomas are monoclo-
nal, MGMT staining was vastly different between tumors,
which again suggested that transcriptional modifications
are involved in regulating MGMT expression [12–14].
The role of p53 in modulating MGMT expression is
controversial. Several studies have suggested an inverse
correlation of p53 with MGMT expression [15, 16]. How-
ever, it has also been shown that accumulation of p53 pro-
tein suppresses MGMT expression and promotes cell
sensitivity to alkylating agents [17–20]. Furthermore, wild-
type p53 protein abrogates MGMT expression by binding
directly to the MGMT promoter or by sequestering spe-
cificity protein 1 (sp1) [9]. Interestingly, p53 appears to
stimulate MGMT expression, and p53 inhibition sensitizes
human glioma cells to TMZ [10, 21]. Additionally, wild-
type p53, rather than mutant p53, promotes MGMT ex-
pression by modulating MGMT methylation by reducing
DNMT1 expression in lung cancer cell lines [22], while
transduction of IMR90 fibroblasts (human fetal lung cells)
with a wild-type p53-adenoviral vector reduced MGMT
expression [19]. In brief, the effect of p53 on MGMT ex-
pression may depend on its level and status in specific tis-
sues. The reasons for these inconsistent findings remain
elusive, and may be cell type dependent [20]. According to
previous studies, high-level p53 is more frequent in ag-
gressive and atypical pituitary adenomas [23], consistent
with a higher incidence of low-level MGMT expression
amongst more aggressive pituitary adenomas [24]. More-
over, although p53 is one of the most commonly in-
activated genes in human cancer, it is rarely mutated in
pituitary adenomas [25]. We therefore asked whether
p53 was involved in mediating prolactinoma MGMT
expression.
To address these questions, we carried out a retrospec-
tive study to evaluate MGMT expression with immuno-
chemistry in a large prolactinoma cohort. Importantly, the
potential mechanisms underpinning the suppression of
MGMT expression, including MGMT promoter methyla-
tion and p53 regulation, were explored.
Methods
Subjects and study protocol
All prolactinoma patients in our center were prescribed
bromocriptine as a first-line treatment. In line with other
reports, resistance to bromocriptine administered in
daily doses (15 mg) for at least 3 months was defined by
an absent or poor response in normalization of prolactin
(PRL) levels (normal PRL levels are less than 25 ng/mL)
[26]. Surgery was considered only for patients who were
drug resistant or unwilling to take drugs. By searching
the tissue database of the First Affiliated Hospital of Sun
Yat-sen University, all prolactinoma patients between
January 2000 and September 2013 with enough paraffin-
embedded tissue specimens for immunostaining were
identified. We screened samples by immunostaining for
growth hormone (GH), prolactin, adrenocorticotropin,
follicle-stimulating hormone, luteinizing hormone, and
thyroid-stimulating hormone. Only patients positive for
prolactin and negative for the other pituitary hormones
were enrolled, and patients treated with radiation before
operation were excluded. Additionally, owing to the het-
erogeneity of the patient population, follow-up duration
was not precise. Considering this study was not designed
to address this question, follow-up information was not
included in the present study. In summary, 136 speci-
mens were included, whose clinical and imaging charac-
teristics were reviewed, including age, sex, imaging
features, and treatment modality. This study was ap-
proved by the Ethics Review Committee of the First
Affiliated Hospital of Sun Yat-sen University. Written in-
formed consent was obtained from patients for the use
of their samples in this study.
Based on magnetic resonance (MR) imaging, a macro-
adenoma was defined by a maximal tumor diameter
of >10 mm, whereas microadenomas were defined with
a maximal tumor diameter of <10 mm. Invasive pituitary
adenoma was defined as the presence of either cavern-
ous sinus, supresellar, or infrasellar invasion. Cavernous
sinus invasion was noted according to the Knosp classifi-
cation [27]. Suprasellar invasion was defined by clear
tumor growth through the diaphragm sella or above the
plane of the inferior optic chiasm. Infrasellar invasion
was determined by tumor growth into the sphenoid
sinus or clivus. According to the 2004 World Health
Organization classification, atypical adenomas were de-
fined by their invasiveness, a MIB-1 proliferation index
greater than 3 %, and an extensive nuclear staining for
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p53 protein [28]. Recurrence was defined by post-
operative imaging studies if a neoplasm presented or
tumor remnant increased in configuration over time and
necessitated further interventions.
Immunohistochemistry
Surgical tissue specimens were routinely formalin-fixed,
paraffin-embedded, and sectioned at 5 μm for immu-
nostaining using streptavidin-biotin. All slides were in-
cubated with mouse monoclonal anti-MGMT at 1:250
dilution (MT3.1), anti-MIB-1 at 1:100 (ab66155), and
rabbit polyclonal anti-p53 at 1:250 dilution (ab17990, all
antibodies from Abcam, Cambridge, UK). MGMT stain-
ing was considered positive only when showing defini-
tive staining of tumor nuclei. Internal positive controls
consisted of endothelial cells. Replacement of a primary
antibody with PBS served as the negative control.
Specimen immunoreactivity was assessed microsco-
pically under ten high-powered fields (×200) by three in-
dependent observers (Hu B, Song BB, and Wang X),
using a semi-quantitative method by estimating the
percentage of positive tumor nuclei. Areas of positive
staining within tumor nuclei and minimal background
reactivity were considered representative and used for
evaluating percentage immunopositivity. MGMT immu-
nostaining was semi-quantitatively scored as 1, <10 %; 2,
10–25 %; 3, 25–50 %, and 4, <50 %, according to positive
nuclear staining. Scores one and two were considered as
low-level or absent MGMT expression, whereas scores
three and four represent intermediate or high MGMT ex-
pression, respectively [29]. The Ki-67 index was defined as
the proportion of MIB-1 positive tumor nuclei on the
basis of a manual count of 500 cells. The p53 antibody
recognizes the N-terminal epitope of both wild-type and
mutant p53, with the p53 labeling index determined by
the percentage of positively stained nuclei.
Methylation-specific PCR
Only 46/136 tumors had sufficient tissue to allow deter-
mination of the methylation status of the MGMT pro-
moter by methylation-specific PCR (MSP). Genomic
DNA was extracted from 24 paraffin-embedded spe-
cimens and 22 frozen samples stored in-80 °C freezer
according to standard protocols (TianGen DNA Mini
Kit, Beijing, China). Methylation patterns were deter-
mined by bisulfite-treated modification, which converts
unmethylated but not methylated cytosines to uracil.
MSP was performed according to the kit protocol of
DNA methylation modification (EZ DNA Methylation-
Gold kit, Zymo Research, USA). Primers were specific
for either methylated or the modified unmethylated
DNA, as previously described [30]. DNA from normal
peripheral blood lymphocytes (PBL) served as a negative
control, and enzymatically methylated DNA from PBL
was used as a positive control. Controls without DNA
were used for each set of MSP assays. Ten microliters
of each 50-μL MSP product was loaded directly onto
nondenaturing 6 % polyacrylamide gels, stained with
ethidium bromide, and examined under ultraviolet
illumination.
Statistical analysis
Associations between clinical, biological, imaging, or mo-
lecular features (MGMT promoter methylation, Ki-67 and
p53 expression) and MGMT immunostaining were evalu-
ated by Spearman correlation, χ2 test, or Fisher’s exact
test. For multivariate logistic analysis, a backward elimin-
ation procedure was performed to identify independent
predictors for MGMT expression. Results were expressed
as odds ratios (ORs) with 95 % confidence intervals (95 %
CIs). All statistical analysis was performed with SPSS




Patients (136: 81 were female, 55 were male) were
retrospectively reviewed, including 121 macroadenomas
and 16 giant adenomas (>40 mm). The median age at
prolactinoma diagnosis was 32 years (range, 14-75
years). Because cabergoline remains unavailable in
China, bromocriptine was the only choice among the
drugs for prolactinoma patients. Seventy-three patients
were resistant to bromocriptine, and 38 patients were
intolerant to bromocriptine as indicated by adverse
sides. The medical history of the other 25 patients was
unclear. The median maximum diameter of tumors was
20.5 mm (range, 5–70 mm). In addition, 60 invasive, 25
recurrent, and 21 atypical prolactinomas were identified
in the present study.
Immunohistochemistry results
MGMT, Ki-67, and p53 all displayed nuclear staining
(Fig. 1). Among the 136 prolactinoma specimens,
MGMT immunopositivity was <10 % in 61 (44.9 %),
10–25 % in 45 (33.1 %), 25–50 % in 14 (10.3 %),
and >50 % in 16 (11.8 %) of the tumors. Therefore, the
majority of the specimens (78 %) showed low-level or no
MGMT immunostaining. In addition, 46/60 invasive
prolactinomas (76.7 %) and 18/25 recurrent species
(72 %) had low-level or no MGMT expression. Fifty-
seven specimens from patients resistant to bromocrip-
tine and 29 of the intolerant patients showed low-level
of no MGMT expression, respectively. There was no
significant difference in MGMT expression between
samples obtained from the two groups (78.08 vs.
76.32 %, p = 0.182).
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Both p53 and age were independent of other factors for
MGMT expression
The association of MGMT expression with age, max-
imum diameter, p53, and Ki-67 staining were evaluated
by spearman correlation analysis. Correlations with sex,
recurrence, invasive, and atypical features were evaluated
by χ2 or Fisher’s exact test. The results showed that
MGMT immunoexpression was positively correlated
with age (r = 0.251, p = 0.003). In contrast, there was an
inverse correlation between MGMT immunoreactivity
and p53 staining (r = −0.153, p = 0.021). More import-
antly, low-level or silenced MGMT expression was more
frequently observed in atypical prolactinomas (p = 0.044)
(Table 1). However, there were no statistically significant
associations between MGMT immunostaining and sex,
maximum tumor diameter, invasiveness, or recurrence
(p > 0.05). As expected, the Ki-67 index correlated with
p53 (r = 0.278, p = 0.001), tumor invasiveness (r = 0.241,
p = 0.005), the maximum diameter (r = 0.38, p < 0.0001)
as well as p53 staining (p < 0.05), but not with MGMT
positive staining and recurrence (p > 0.05).
Seven covariates, including age, sex, recurrence, Ki-67
index, p53 staining, and the presence of atypical and in-
vasive features, were analyzed in multiple logistic regres-
sion models. Despite the strong correlations between the
Ki-67 index, p53 staining, and the presence of atypical
Fig. 1 MGMT, Ki-67, and p53 protein immunohistochemistry. A prolactinoma tissue demonstrates weak (a) and strong (b) nuclear staining of
MGMT. The endothelial cell (arrow) acts as an internal positive control (original magnification 400×). Negative (c) and positive (d) staining of Ki-67,
and negative (e) and positive (f) staining of p53 protein are shown in prolactinoma specimens (original magnification 400×)
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features, they were not included in the model. Only p53
staining (OR = 0.218, 95 % confidence interval [CI]:
0.075–0.623, p = 0.005) and age (OR = 1.048, 95 % confi-
dence interval [CI]: 1.01–1.086, p = 0.021) were deter-
mined independently of the other factors for MGMT
expression.
MSP results
MSP was used to evaluate MGMT promoter methyla-
tion status in 46 samples, with methylation confirmed in
10 (21.7 %) specimens, all of which were shown to have
low level MGMT staining, with seven exhibiting <10 %
staining, and three with 10–25 % positive. Unmethylated
MGMT promoters were detected in the remaining 36
(78.3 %) specimens, which included 23 samples with
low-level MGMT expression. In the 23 specimens dis-
playing low-level MGMT immunoexpression without a
methylated MGMT promoter, 11 were positive for p53,
which again indicated a potential role for p53 in regulat-
ing prolactinoma MGMT expression. By Spearman cor-
relation analysis, both p53 protein expression (r = −0.33,
p = 0.025) and methylated MGMT promoter (r = −0.331,
p = 0.025) were negatively associated with MGMT ex-
pression. Because no specimen with a methylated pro-
moter showed high-level MGMT staining, MGMT
promoter methylation was not included in the logistic
regression analysis. Multivariate logistical analysis
showed that age (OR = 1.127. 95 % CI 1.027–1.236,
p = 0.012) and p53 staining (OR = 0.116. 95 % CI 0.018–
0.761, p = 0.025) were independently negatively associ-
ated with MGMT expression (Table 2).
Discussion
Recently, increasing evidence suggests that TMZ might
be a rational therapeutic option for patients with refrac-
tory pituitary adenomas and carcinomas [3, 5]. Sur-
prisingly, prolactinomas appear to be more sensitive to
TMZ than the other types of pituitary adenomas [5].
Meanwhile, successful TMZ therapy is closely associated
with low-level MGMT expression [3, 6]. Herein, profil-
ing MGMT expression and understanding its potential
modulation in prolactinomas may pave the way for
TMZ treatment of prolactinomas. Our study evaluated
MGMT expression in a large cohort of atypical prolacti-
nomas, the majority of which exhibited low-level expres-
sion. Systematic analysis showed that MGMT staining
was negatively associated with its promoter methylation
and p53 protein expression, indicating both epigenetic
and transcriptional mechanisms are potentially involved
in modulating MGMT expression in prolactinomas.
The MGMT status in pituitary adenomas has been
evaluated in several previous studies by immunostaining,
showing variable expression levels in different subtypes
of pituitary adenomas [7, 8, 24, 31–33]. McCormack
et al. first compared MGMT levels in different types of
pituitary adenomas [7]. Their results showed that only
13 % of tumors (n = 88) demonstrated low-level MGMT
expression (<10 %); however, 50 % of the prolactinomas
exhibited low-level MGMT expression. Lau et al. exam-
ined MGMT expression in 30 pituitary carcinomas and
30 pituitary adenomas [29]. Low MGMT expression
(<25 %) was found in 57 % of carcinomas and 60 % of
invasive adenomas. Similarly, 80 % of the prolactinomas
(n = 10) showed low-level MGMT expression. In non-
functional pituitary adenomas, low MGMT expression
(≤50 %) was confirmed in only 24 % of samples as re-
ported by Widhalm et al. (n = 45) [31]. In addition,
Whitelaw et al. summarized all published TMZ-treated
prolactinomas, with 86.7 % staining positive at less than
10 % [5]. Thus, prolactinomas seem more likely to have
Table 1 The correlation between MGMT immuno-expression
and clinical characteristics (n = 136)
MGMT immuno-expression
Variables Low level or no




Age (mean ± SD) (year) 31.34 ± 11.88 37.8 ± 11.68 0.009
Maximum diameter
(mean ± SD) (mm)













Age and tumor maximum diameter were compared with the Student’s t-test.
Categorical analysis of variables was performed using either the χ2 test or
Fisher’s exact test, as appropriate
Table 2 Univariate and multivariate regression analysis
showing the independent determinants of the expression of
MGMT (n = 46)
Univariate Multivariate
Independent variables OR P value OR (95 % Cls) P value
Age 1.104 0.014 1.127 (1.027–1.236) 0.012
Gender 1.651 0.389
Ki-67 index 2.321 0.237
p53 staining 0.171 0.036 0.116 (0.018–0.761) 0.025
Except for sex and Ki-67, variables with a P value of <0.05 in the univariate
regression analysis were included in the multivariate model. Only significant
P values are shown in the multivariate model
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reduced MGMT expression compared with other sub-
types. Consistent with previous studies, 78 % of samples
stained positive for low-level MGMT (25 %), with 44.9 %
at less than 10 %. However, in two recent reports, low-
level MGMT expression (<25 %) was observed in 91.6 %
of GH adenomas (n = 36) [32], and 60 % of pituitary cor-
ticotroph adenomas (n = 40) [24]. More cases are needed
to create a more accurate profile of MGMT expression
in each subtype of pituitary adenoma.
MGMT expression tended to be more common in
aggressive subtypes. Takeshita et al. reported 71 % of
Crooke’s cell adenomas (n = 7) had very low MGMT ex-
pression (<5 %), whereas only 1/17 ordinary corticotroph
adenomas showed low MGMT expression [34]. How-
ever, in another study, only 50 % of Crooke’s cell
adenomas (n = 12) showed low-level MGMT staining, al-
though all subtype I pituitary adenomas (n = 7) were
immunopositive at <10 % [24]. Fealey et al. showed that
all silent subtype 3 (SS3) pituitary adenomas (n = 23)
had reduced MGMT expression (≤50 %), and 78 % were
negative for MGMT immunoreactivity [35]. In contrast,
Salehi et al. reported that 50 % of carcinomas (n = 10)
and 92 % (n = 11) of SS3 pituitary adenomas showed low
MGMT staining (<10 %) [12]. Similarly, we observed
low-level MGMT expression more frequently in atypical
prolactinomas. However, no significant relationship was
found between MGMT staining and tumor size, recur-
rence, invasiveness, or Ki-67 index, which is similar to
previous studies [3, 24, 32]. Nevertheless, these clues
suggest a rational approach to administer TMZ to re-
fractory adenomas.
In the present study, prolactinoma patients with low-
level MGMT expression were younger than those with
elevated expression. This is consistent with the obser-
vation that MGMT immunoreactivity was inversely
correlated with patient age, again suggesting a role for
methylation in regulating MGMT expression [36], al-
though this is also likely a reflection of the younger age
of the prolactinoma patients. However, no apparent
relationship between MGMT expression and age was
observed in patients with Cushing disease or GH aden-
omas [24, 32], which might be because of the various
mechanisms of MGMT expression in different adenoma
subtypes.
The precise mechanisms responsible for MGMT ex-
pression remain poorly understood. MGMT promoter
methylation, well known as one of the proposed mecha-
nisms underlying suppression of MGMT expression, is
associated with the reduced MGMT protein level com-
monly seen in primary human neoplasms [37]. More-
over, MGMT promoter methylation is correlated with
improved response to TMZ in glioblastoma patients [2].
However, few systematic studies are available that examine
the association between MGMT promoter methylation
and MGMT expression in pituitary adenomas [5, 6, 12].
Therefore, the role of promoter methylation in regulating
MGMT expression in pituitary adenomas remains contro-
versial. In the study by McCormack et al., only 9 % of the
cases (n = 46) displayed methylated promoters, although a
significant inverse correlation was found between MGMT
expression and promoter methylation [7]. This inverse re-
lationship between MGMT expression and promoter
methylation was also observed here in all ten tumors
(21.7 %), with methylated promoters showing low-level
MGMT staining. In addition, MGMT promoter methy-
lation tended to be more common in the aggressive
pituitary adenomas, with 33 % in pituitary carcinomas,
42 % in SS3 adenomas, and 43 % in aggressive pituitary
adenoma [12, 38]. This is consistent with the fact that the
aggressive subtypes are associated with low-level MGMT
expression. In contrast, a significant relationship between
methylation status and MGMT immunoexpression was
not observed in the carcinoma and SS3 pituitary aden-
omas [12], and a methylated MGMT promoter did not
tend to correlate with a response to TMZ exposure [5].
Together, MGMT promoter methylation is likely to
explain low-level MGMT expression in some, but not all,
pituitary tumors, as further regulation may occur at the
transcriptional, post transcriptional, or translational levels.
The tumor suppressor p53 is expressed in response to
stress, and plays a central role in pituitary adenoma
pathogenesis [25]. Although p53 is widely mutated in
many human cancers, it is rarely mutated in pituitary
adenomas [25]. In the present study, almost 40 % of the
samples had 5 % or more positive staining of p53, which
was negatively associated with MGMT immunoexpres-
sion, as has been confirmed in other human cancers, in-
cluding breast, lung, and pancreatic [15, 16]. Moreover,
MGMT suppression was associated with p53 activation,
and accumulation of p53 increased the cell response to
alkylation agents [17–20]. Additional evidence revealed
that wild-type p53 suppresses MGMT by binding dir-
ectly to the MGMT promoter or by sequestering Sp1
[9]. On the contrary, some reports suggest that p53
may positively regulate MGMT expression, and that
p53 inhibition sensitizes human glioma cells to TMZ
[10, 21]. Expression of wild-type p53 was necessary for
inducing MGMT mRNA and protein by ionizing radi-
ation [18]. Additionally, wild-type p53 rather than mu-
tant p53 promoted MGMT expression by modulating
MGMT methylation, presumably by reducing DNMT1
(DNA-methyltransferase 1) expression in lung cancer
cell lines [22].
Our study has several limitations. First, the number of
specimens for evaluating promoter methylation was rela-
tively small, which may fail to describe the complete pic-
ture of prolactinoma MGMT promoter methylation and
its correlation with tumor and patient characteristics.
Jiang et al. BMC Cancer  (2015) 15:644 Page 6 of 8
Second, because of insufficient tumor tissue, we failed to
detect MGMT expression by western blot, but relied
solely on immunohistochemistry staining. The lack of
standard scoring, and operator variability, made it more
difficult to determine accurately the level of MGMT ex-
pression. Therefore, three independent observers assessed
immunoreactivity, with the data analyzed using the most
widely used methods. Third, patients in China have no ex-
cess to cabergoline. Some patients included in the study
may have been treated with cabergoline and not needed
surgery or temozolomide treatment. Moreover, these data
are not applicable to all prolactinoma patients, but only to
the type of specimens analyzed here. Thus, it is difficult to
say whether MGMT reduced expression was a general
characteristic of prolactinomas. In addition, because all
patients were not treated with TMZ before or after sur-
gery, a possible relationship between MGMT level and
TMZ intolerance could not be established. Finally, be-
cause of the nature of retrospective studies, the causality
of MGMT silencing and promoter methylation or p53
protein activation could not be established. Although an
inverse correlation between p53 and MGMT was found, it
was weak. Nevertheless, our results strongly suggest that
promoter methylation is not the sole mechanism under-
lining MGMT silencing in prolactinomas.
Conclusions
The present study is one of the largest reports describing
prolactinoma MGMT expression and its relationship
with patient and tumor characteristics. The prevalence
of low-level MGMT expression in prolactinomas, espe-
cially in atypical prolactinomas, was confirmed, rational-
izing the utility of TMZ as an alternative prolactinoma
treatment. Furthermore, this study is the first to show
that MGMT expression was inversely correlated with
both promoter methylation and p53 protein, implying an
epigenetic and transcriptional modulation in silencing
MGMT expression.
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